Dr Mamounas speaks with ecancertv at SABCS 2016 about the impact of letrozole treatment up to, and beyond, 5 years on disease free survival of post-menopausal women with HR positive breast cancer who have completed previous adjuvant aromatase inhibitory therapy.

From nearly 4000 patients enrolled, he describes a reduction in the that of distant recurrent disease and improvement in breast cancer free interval events, though notes that overall benefits on DFS did not meet statistical significance.

Dr Mamounas also notes an elevated risk of thrombotic events after 2.5 for patients receiving letrozole past that point.

These results were first presented at a press conference session, with video coverage here.